Acute Heart FailureHF-USBNCT04000061
Heart Failure-USB: Prediction and Progression
An observational study of Acute Heart Failure and Acute Coronary Syndrome, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Heart Failure, Acute Coronary Syndrome
- What is being tested?
- medical chart review and data generated by direct IT export
- How many people
- 6,000 participants
- Where
- 1 siteSwitzerland
- Study dates
- 13 Jun 2019to 4 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients that were hospitalized at the Universitätsspital Basel/ Switzerland with the diagnosis of ACS or AHF during the years 2010 - 2023
Who may be able to join
- Patients hospitalized with a primary diagnosis of ACS
- Patients hospitalized with a primary or secondary diagnosis of AHF
Who cannot join
- Existence of a documented statement of the patient against the scientific use of clinical data
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Cardiology, University Hospital Basel
Basel, 4031
Christian Mueller, Prof. Dr., +41 61 32 86 549, Christian.mueller@usb.ch
About this study
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
- Conditions
- Acute Heart Failure, Acute Coronary Syndrome
- Being tested
- medical chart review, data generated by direct IT export
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
medical chart reviewOther
data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
data generated by direct IT exportOther
data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
| Study group | Role | What they receive |
|---|---|---|
| acute coronary syndrome (ACS) | Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed. Receives: Other: medical chart review; Other: data generated by direct IT export | |
| acute heart failure (AHF) | Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed. Receives: Other: medical chart review; Other: data generated by direct IT export |
What is being measured
The primary outcome is the main question the study is designed to answer.
number of all-cause death
number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023.
Measured: 1 to 8 years after hospitalization
number of HF hospitalizations
number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023
Measured: 1 to 8 years after hospitalization
number of cardiovascular death
number of cardiovascular death in patients hospitalized with ACS and AHF
Measured: 1 to 8 years after hospitalization
number of cardiovascular hospitalizations
number of cardiovascular hospitalizations
Measured: 1 to 8 years after hospitalization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2019
- Study start13 Jun 2019
- Primary completion4 Apr 2027 (estimated)
- Study completion4 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 6,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christian Müller, Prof. Dr., Principal investigator, Cardiology University Hospital Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04000061
- Sponsor's protocol ID
- 2019-00956
- Other IDs
- 2019
- Acronym
- HF-USB
- Status last verified
- Sep 2026
- First submitted
- 25 Jun 2019
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Heart Failure-USB: Prediction and Progression
- ClinicalTrials.gov ID
- NCT04000061
- Acronym / sponsor ID
- HF-USB / 2019-00956
- Conditions
- Acute Heart Failure, Acute Coronary Syndrome
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 6,000 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 13 Jun 2019 (actual)
- Primary completion
- 4 Apr 2027 (estimated)
- Study completion
- 4 Apr 2027 (estimated)
- First posted
- 27 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| acute coronary syndrome (ACS) | – | Other: medical chart review, Other: data generated by direct IT exportOutcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed. |
| acute heart failure (AHF) | – | Other: medical chart review, Other: data generated by direct IT exportOutcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients that were hospitalized at the Universitätsspital Basel/ Switzerland with the diagnosis of ACS or AHF during the years 2010 - 2023
Key inclusion criteria (2 listed)
- Patients hospitalized with a primary diagnosis of ACS
- Patients hospitalized with a primary or secondary diagnosis of AHF
Key exclusion criteria (1 listed)
- Existence of a documented statement of the patient against the scientific use of clinical data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| medical chart reviewdata generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations | Other | acute coronary syndrome (ACS), acute heart failure (AHF) |
| data generated by direct IT exportdata generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data | Other | acute coronary syndrome (ACS), acute heart failure (AHF) |
Primary outcome
number of all-cause death
Time frame: 1 to 8 years after hospitalization
number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023.
number of HF hospitalizations
Time frame: 1 to 8 years after hospitalization
number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023
number of cardiovascular death
Time frame: 1 to 8 years after hospitalization
number of cardiovascular death in patients hospitalized with ACS and AHF
number of cardiovascular hospitalizations
Time frame: 1 to 8 years after hospitalization
number of cardiovascular hospitalizations
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Heart Failure
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Recruiting
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
Cardiogenic Shock, Acute Myocardial Infarction of Inferior Wall
RecruitingPhase 4
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
Pulmonary Edema, Congestive Heart Failure
RecruitingObservational study
Exploratory Study on Bio-signal Telemonitoring Using Electronic Textiles in a Pediatric Acute and Critical Care Setting
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Christian Müller, Prof. Dr. principal investigator
Cardiology University Hospital Basel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Heart Failure and Acute Coronary Syndrome, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christian Müller, Prof. Dr. (0041 6132 86 549, Christian.mueller@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of all-cause death (time frame: 1 to 8 years after hospitalization). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.